Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD): Measurement Properties of Novel Patient-Reported Symptom Measures.


Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
05 2022
Historique:
received: 23 06 2021
revised: 27 10 2021
accepted: 17 11 2021
pubmed: 14 12 2021
medline: 11 5 2022
entrez: 13 12 2021
Statut: ppublish

Résumé

The Asthma Daytime Symptom Diary (ADSD) and the Asthma Nighttime Symptom Diary (ANSD) were developed to meet the need for standardized patient-reported measures of asthma symptoms to assess treatment trial outcomes in adults and adolescents. To determine scoring and evaluate the measurement properties of the ADSD/ANSD. Adolescents (12-17 years) and adults (18+ years) with asthma completed draft 8-item electronic versions of the ADSD/ANSD for 10 days alongside the Adult Asthma Symptom Daily Scales (AASDS) and a Patient Global Impression of Severity (PGIS). Using classical and modern psychometric methods, initial analyses evaluated the performance of ADSD/ANSD items to inform scoring. Subsequent analyses evaluated the reliability and validity of ADSD/ANSD scores. A demographically and clinically diverse sample (n = 130 adolescents; n = 89 adults) was recruited. Item performance was generally strong. However, items assessing chest pressure and mucus/phlegm demonstrated redundancy and poorer performance and were removed. Principal-components analysis, confirmatory factor analysis, and item response theory supported combining items to form 6-item total ADSD/ANSD scores. Internal consistency (α = 0.94-0.95) and test-retest reliability (intraclass correlation coefficient = 0.86-0.95) were strong. Strong correlations (r = 0.72-0.80) were observed between ADSD scores and AASDS items assessing asthma symptom frequency, bother, and impact on activities. Significant differences (P < .001) in mean ADSD/ANSD scores were observed between groups categorized by asthma severity (PGIS), asthma control, inhaler use, nebulizer use, activity limitations, and nighttime awakenings. The ADSD/ANSD items and scores demonstrated strong reliability and validity. Implementation of the measures in interventional studies will enable the evaluation of responsiveness and meaningful within-patient change.

Sections du résumé

BACKGROUND
The Asthma Daytime Symptom Diary (ADSD) and the Asthma Nighttime Symptom Diary (ANSD) were developed to meet the need for standardized patient-reported measures of asthma symptoms to assess treatment trial outcomes in adults and adolescents.
OBJECTIVE
To determine scoring and evaluate the measurement properties of the ADSD/ANSD.
METHODS
Adolescents (12-17 years) and adults (18+ years) with asthma completed draft 8-item electronic versions of the ADSD/ANSD for 10 days alongside the Adult Asthma Symptom Daily Scales (AASDS) and a Patient Global Impression of Severity (PGIS). Using classical and modern psychometric methods, initial analyses evaluated the performance of ADSD/ANSD items to inform scoring. Subsequent analyses evaluated the reliability and validity of ADSD/ANSD scores.
RESULTS
A demographically and clinically diverse sample (n = 130 adolescents; n = 89 adults) was recruited. Item performance was generally strong. However, items assessing chest pressure and mucus/phlegm demonstrated redundancy and poorer performance and were removed. Principal-components analysis, confirmatory factor analysis, and item response theory supported combining items to form 6-item total ADSD/ANSD scores. Internal consistency (α = 0.94-0.95) and test-retest reliability (intraclass correlation coefficient = 0.86-0.95) were strong. Strong correlations (r = 0.72-0.80) were observed between ADSD scores and AASDS items assessing asthma symptom frequency, bother, and impact on activities. Significant differences (P < .001) in mean ADSD/ANSD scores were observed between groups categorized by asthma severity (PGIS), asthma control, inhaler use, nebulizer use, activity limitations, and nighttime awakenings.
CONCLUSIONS
The ADSD/ANSD items and scores demonstrated strong reliability and validity. Implementation of the measures in interventional studies will enable the evaluation of responsiveness and meaningful within-patient change.

Identifiants

pubmed: 34896298
pii: S2213-2198(21)01362-3
doi: 10.1016/j.jaip.2021.11.026
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1249-1259

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Adam Gater (A)

Adelphi Values Ltd, Bollington, Cheshire, United Kingdom. Electronic address: adam.gater@adelphivalues.com.

Linda Nelsen (L)

GlaxoSmithKline, Collegeville, Pa.

Cheryl D Coon (CD)

Outcometrix, St Petersburg, Fla.

Sonya Eremenco (S)

Patient-Reported Outcome Consortium, Critical Path Institute, Tucson, Ariz.

Sean O'Quinn (S)

AstraZeneca, Gaithersburg, Md.

Asif H Khan (AH)

Sanofi, Chilly-Mazarin, France.

Laurent Eckert (L)

Sanofi, Chilly-Mazarin, France.

Hannah Staunton (H)

Roche Products Limited, Welwyn Garden City, Hertfordshire, United Kingdom.

Nicola Bonner (N)

Adelphi Values Ltd, Bollington, Cheshire, United Kingdom.

Rebecca Hall (R)

Adelphi Values Ltd, Bollington, Cheshire, United Kingdom.

Jerry A Krishnan (JA)

University of Illinois at Chicago, Chicago, Ill.

Stuart Stoloff (S)

University of Nevada, Reno, Nev.

Michael Schatz (M)

Kaiser Permanente Medical Center/Kaiser Foundation Hospital, San Diego, Calif.

John Haughney (J)

Queen Elizabeth University Hospital, Glasgow, United Kingdom.

Stephen Joel Coons (SJ)

Patient-Reported Outcome Consortium, Critical Path Institute, Tucson, Ariz.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH